IDEC-C2B8 (rituximab) anti-CD20 monoclonal antibody therapy in patients with pretreated low-grade non-Hodgkin's lymphoma.

被引：0
|
作者：
Schwandt, KU [1 ]
Bremer, K [1 ]
机构：
[1] Augusta Kranken Anstalt, Bochum, Germany
来源：
ANNALS OF ONCOLOGY | 2000年 / 11卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
477P
引用
收藏
页码：105 / 105
页数：1
相关论文
共 50 条
  • [1] IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma
    Maloney, DG
    GrilloLopez, AJ
    White, CA
    Bodkin, D
    Schilder, RJ
    Neidhart, JA
    Janakiraman, N
    Foon, KA
    Liles, TM
    Dallaire, BK
    Wey, K
    Royston, I
    Davis, T
    Levy, R
    BLOOD, 1997, 90 (06) : 2188 - 2195
  • [2] IDEC-C2B8 anti-CD20 (Rituximab) immunotherapy in patients with low-grade non-Hodgkin's lymphoma and lymphoproliferative disorders: evaluation of response on 48 patients
    Nguyen, DT
    Amess, JA
    Doughty, H
    Hendry, L
    Diamond, LW
    EUROPEAN JOURNAL OF HAEMATOLOGY, 1999, 62 (02) : 76 - 82
  • [3] Extended Rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma
    Piro, LD
    White, CA
    Grillo-López, AJ
    Janakiraman, N
    Saven, A
    Beck, TM
    Varns, C
    Shuey, S
    Czuczman, M
    Lynch, JW
    Kolitz, JE
    Jain, V
    ANNALS OF ONCOLOGY, 1999, 10 (06) : 655 - 661
  • [4] Targeted anti-cancer therapy using rituximab, a chimaeric anti-CD20 antibody (IDEC-C2B8) in the treatment of non-Hodgkin's B-cell lymphoma
    Anderson, DR
    GrilloLopez, A
    Varns, C
    Chambers, KS
    Hanna, N
    BIOCHEMICAL SOCIETY TRANSACTIONS, 1997, 25 (02) : 705 - 708
  • [5] Treatment of B cell low grade non-Hodgkin's lymphoma (NHL) with anti-CD20 monoclonal antibody Rituximab®
    Federico, M
    Clo, V
    Vinci, G
    Sacchi, S
    ANNALS OF ONCOLOGY, 1998, 9 : 32 - 32
  • [6] Biodistribution and kinetics of 131I-labelled anti-CD20 MAB IDEC-C2B8 (rituximab) in relapsed non-Hodgkin's lymphoma
    Klemens Scheidhauer
    Ingo Wolf
    Hans-Joachim Baumgartl
    Christoph von Schilling
    Burkhard Schmidt
    Günther Reidel
    Christian Peschel
    Markus Schwaiger
    European Journal of Nuclear Medicine and Molecular Imaging, 2002, 29 : 1276 - 1282
  • [7] Biodistribution and kinetics of 131I-labelled anti-CD20 MAB IDEC-C2B8 (rituximab) in relapsed non-Hodgkin's lymphoma
    Scheidhauer, K
    Wolf, I
    Baumgartl, HJ
    von Schilling, C
    Schmidt, B
    Reidel, G
    Peschel, C
    Schwaiger, M
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2002, 29 (10) : 1276 - 1282
  • [8] Anti-CD20 monoclonal antibody therapy for non-Hodgkin's lymphoma
    White, CA
    Weaver, R
    Royston, I
    MINERVA BIOTECNOLOGICA, 1998, 10 (03) : 108 - 116
  • [9] IDEC-C2B8 chimeric anti-CD20 antibody (MAB): Safety and clinical activity in the treatment of patients (PTS) with relapsed low-grade or follicular (IWF:A-D) non-Hodgkin's lymphoma (NHL)
    GrilloLopez, AJ
    Varns, C
    Waldichuk, C
    Dallaire, BK
    Rosenberg, J
    McClure, A
    Shen, D
    BRITISH JOURNAL OF HAEMATOLOGY, 1996, 93 : 1072 - 1072
  • [10] Y-90 anti-CD20 monoclonal antibody (IDEC-Y2B8) dosimetry calculated from In-111 anti-CD20 in patients with low and intermediate grade B-cell non-Hodgkin's lymphoma.
    Wiseman, GA
    Witzig, TE
    Dunn, WL
    Chin, P
    Salinger, AM
    JOURNAL OF NUCLEAR MEDICINE, 1997, 38 (05) : 1062 - 1062
12345